First-Line Antiretroviral Regimen Failure and Determinants in an Urban HIV Clinic at Phramongkutklao Hospital, Bangkok, Thailand: 20 Years Experience

References

• Panel on antiretroviral guidelines for adults and adolescents: guidelines for the use of antiretroviral agents in adults and adolescents with HIV [Internet]. Department of Health and Human Services; 2020. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed March 22, 2020.
   Google Scholar
• d’Arminio Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian cohort of antiretroviral-naïve patients. AIDS. 2000;14(5):499–507. doi:10.1097/00002030-200003310-00005
   PubMed Web of Science ®Google Scholar
• Mocroft A, Youle M, Moore A, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS. 2001;15(2):185–194. doi:10.1097/00002030-200101260-00007
   PubMed Web of Science ®Google Scholar
• Paredes R, Lalama CM, Ribaudo HJ, et al. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis. 2010;201(5):662–671. doi:10.1086/650543
   Web of Science ®Google Scholar
• Chasombat S, McConnell MS, Siangphoe U, et al. National expansion of antiretroviral treatment in Thailand, 2000–2007: program scale-up and patient outcomes. J Acquir Immune Defic Syndr. 2009;50(5):506–512. doi:10.1097/QAI.0b013e3181967602
   PubMed Web of Science ®Google Scholar
• Thailand National Guidelines on HIV/AIDS Treatment and Prevention 2017 [Internet]; 2017. Available from: http://www.thaiaidssociety.org. Accessed March 22, 2020.
   Google Scholar
• Ayalew MB, Kumilachew D, Belay A, et al. First-line antiretroviral treatment failure and associated factors in HIV patients at the University of Gondar Teaching Hospital, Gondar, Northwest Ethiopia. HIV AIDS. 2016;8:141–146. doi:10.2147/HIV.S112048
   Google Scholar
• Robbins GK, Daniels B, Zheng H, Chueh H, Meigs JB, Freedberg KA. Predictors of antiretroviral treatment failure in an urban HIV clinic. J Acquir Immune Defic Syndr. 2007;44(1):30–37. doi:10.1097/01.qai.0000248351.10383.b7
   PubMed Web of Science ®Google Scholar
• Ayele G, Tessema B, Amsalu A, Ferede G, Yismaw G. Prevalence and associated factors of treatment failure among HIV/AIDS patients on HAART attending University of Gondar Referral Hospital Northwest Ethiopia. BMC Immunol. 2018;19(1):37. doi:10.1186/s12865-018-0278-4
   PubMed Web of Science ®Google Scholar
• Hassan AS, Nabwera HM, Mwaringa SM, et al. HIV-1 virologic failure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya: a cross-sectional study. AIDS Res Ther. 2014;11(1):9. doi:10.1186/1742-6405-11-9
   Web of Science ®Google Scholar
• Khienprasit N, Chaiwarith R, Sirisanthana T, Supparatpinyo K. Incidence and risk factors of antiretroviral treatment failure in treatment-naïve HIV-infected patients at Chiang Mai University Hospital, Thailand. AIDS Res Ther. 2011;8(1):42. doi:10.1186/1742-6405-8-42
   Web of Science ®Google Scholar
• WHO Guideline Review committee. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for public health approach [Internet]. World Health Organization; 2013. Available from: https://www.who.int/hiv/pub/arv/arv-2016/en/. Accessed march 22, 2020.
   Google Scholar
• Sidibé M, Loures L, Samb B. The UNAIDS 90–90–90 target: a clear choice for ending AIDS and for sustainable health and development. J Int AIDS Soc. 2016;19.
   Web of Science ®Google Scholar
• Bulage L, Ssewanyana I, Nankabirwa V, et al. Factors associated with virological non-suppression among HIV-positive patients on antiretroviral therapy in Uganda, August 2014–July 2015. BMC Infect Dis. 2017;17.
   Web of Science ®Google Scholar
• Hailu GG, Hagos DG, Hagos AK, Wasihun AG, Dejene TA. Virological and immunological failure of HAART and associated risk factors among adults and adolescents in the Tigray region of Northern Ethiopia. PLoS One. 2018;13(5):e0196259. doi:10.1371/journal.pone.0196259
   PubMed Web of Science ®Google Scholar
• Group TISS. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807. doi:10.1056/NEJMoa1506816
   Web of Science ®Google Scholar
• Ahmed T, Borthwick NJ, Gilmour J, Hayes P, Dorrell L, Hanke T. Control of HIV-1 replication in vitro by vaccine-induced human CD8(+) T cells through conserved subdominant Pol epitopes. Vaccine. 2016;34(9):1215–1224. doi:10.1016/j.vaccine.2015.12.021
   PubMed Web of Science ®Google Scholar
• Lindqvist M, van Lunzen J, Soghoian DZ, et al. Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J Clin Invest. 2012;122(9):3271–3280. doi:10.1172/JCI64314
   PubMed Web of Science ®Google Scholar
• Perno CF, Ceccherini-Silberstein F, De Luca A, et al. Virologic correlates of adherence to antiretroviral medications and therapeutic failure. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S118–22. doi:10.1097/00126334-200212153-00006
   PubMed Web of Science ®Google Scholar
• Turner BJ. Adherence to antiretroviral therapy by human immunodeficiency virus–infected patients. J Infect Dis. 2002;185(s2):S143–S51. doi:10.1086/340197
   PubMed Web of Science ®Google Scholar
• Vriesendorp R, Cohen A, Kristanto P, et al. Adherence to HAART therapy measured by electronic monitoring in newly diagnosed HIV patients in Botswana. Eur J Clin Pharmacol. 2007;63(12):1115–1121. doi:10.1007/s00228-007-0369-2
   Web of Science ®Google Scholar
• Segeral O, Madec Y, Ban B, et al. Simplified assessment of antiretroviral adherence and prediction of virological efficacy in HIV-infected patients in cambodia. AIDS Res Treat. 2010;2010:142076. doi:10.1155/2010/142076
   Google Scholar
• Saberi P, Catz SL, Leyden WA, et al. Antiretroviral therapy adherence and use of an electronic shared medical record among people living with HIV. AIDS Behav. 2015;19(Suppl 2(0 2)):177–185. doi:10.1007/s10461-014-0982-x
   Web of Science ®Google Scholar
• Hare AQ, Ordóñez CE, Johnson BA, et al. Gender-specific risk factors for virologic failure in KwaZulu-Natal: automobile ownership and financial insecurity. AIDS Behav. 2014;18(11):2219–2229. doi:10.1007/s10461-014-0849-1
   Web of Science ®Google Scholar
• Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131(2):81–87. doi:10.7326/0003-4819-131-2-199907200-00002
   PubMed Web of Science ®Google Scholar
• Mujugira A, Celum C, Tappero JW, Ronald A, Mugo N, Baeten JM. Younger age predicts failure to achieve viral suppression and virologic rebound among HIV-1-infected persons in serodiscordant partnerships. AIDS Res Hum Retroviruses. 2016;32(2):148–154. doi:10.1089/aid.2015.0296
   PubMed Web of Science ®Google Scholar
• Zeleke A. Prevalence of antiretroviral treatment failure and associated factors in HIV infected children on antiretroviral therapy at Gondar University Hospital, retrospective cohort study. Int J Med Med Sci. 2016;8(11):125–132.
   Google Scholar
• Musa BM, Musa B, Muhammed H, Ibrahim N, Musa AG. Incidence of tuberculosis and immunological profile of TB/HIV co-infected patients in Nigeria. Ann Thorac Med. 2015;10(3):185–192. doi:10.4103/1817-1737.160838
   PubMed Web of Science ®Google Scholar
• Zhang Q, Sugawara I. Immunology of tuberculosis. World J Exp Med. 2012;2(4):70–74. doi:10.5493/wjem.v2.i4.70
   Google Scholar
• Yuan D, Liu M, Jia P, et al. Prevalence and determinants of virological failure, genetic diversity and drug resistance among people living with HIV in a minority area in China: a population-based study. BMC Infect Dis. 2020;20(1):443. doi:10.1186/s12879-020-05124-1
   PubMed Web of Science ®Google Scholar
• Liégeois F, Vella C, Eymard-Duvernay S, et al. Virological failure rates and HIV-1 drug resistance patterns in patients on first-line antiretroviral treatment in semirural and rural Gabon. J Int AIDS Soc. 2012;15(2):17985. doi:10.7448/IAS.15.2.17985
   Web of Science ®Google Scholar
• Penda CI, Moukoko CEE, Koum DK, et al. Feasibility and utility of active case finding of HIV-infected children and adolescents by provider-initiated testing and counselling: evidence from the Laquintinie hospital in Douala, Cameroon. BMC Pediatr. 2018;18(1):259. doi:10.1186/s12887-018-1235-3
   Web of Science ®Google Scholar
• Muessig KE, Nekkanti M, Bauermeister J, Bull S, Hightow-Weidman LB. A systematic review of recent smartphone, Internet and Web 2.0 interventions to address the HIV continuum of care. Curr HIV/AIDS Rep. 2015;12(1):173–190. doi:10.1007/s11904-014-0239-3
   PubMed Web of Science ®Google Scholar
• Hightow-Weidman LB, Muessig KE, Bauermeister J, Zhang C, LeGrand S. Youth, technology, and HIV: recent advances and future directions. Curr HIV/AIDS Rep. 2015;12(4):500–515. doi:10.1007/s11904-015-0280-x
   PubMed Web of Science ®Google Scholar
• Elgalib A, Al-Sawafi H, Kamble B, Al-Harthy S, Al-Sariri Q. Multidisciplinary care model for HIV improves treatment outcome: a single-centre experience from the Middle East. AIDS Care. 2018;30(9):1114–1119. doi:10.1080/09540121.2018.1479028
   PubMed Web of Science ®Google Scholar